C4 Therapeutics Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ 18.93, 20.74, 16.18, 775.7, 2613.2 ], "ebit_estimate": [ -133.9, -159.84, -187, -200.67, -102.67 ], "ebitda_estimate": [ -116, -127, -151, null, null ], "net_income_estimate": [ -117.58, -144.72, -168.25, -175.33, -74.67 ], "per_share_eps_estimate": [ -0.93, -0.97, -1.28, -1.15, -0.57 ], "eps_nri_estimate": [ -0.93, -0.97, -1.28, -1.15, -0.57 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ 0.31, 1.04, null, null, null ], "pretax_income_estimate": [ -118.23, -152.38, -204.9, -198.5, -100 ], "operating_cash_flow_per_share_estimate": [ -0.72, -0.89, -1.6, 6.28, 23.71 ], "roa_estimate": [ -38.9, -76, -1.29, 80.1, 74.5 ], "roe_estimate": [ -191.07, -192.1, 162.4, 116.6, 81 ], "gross_margin_estimate": [ 100, 100, 100, 91.7, 92 ], "operating_cash_flow_estimate": [ -90.77, -112.21, -201.72, 791.75, 2989.24 ], "pettm_estimate": [ 0, 0, 0, 0, 0 ], "long_term_growth_rate_mean": 0, "long_term_revenue_growth_rate_mean": "-20.58", "future_per_share_eps_estimate_growth": null, "future_eps_nri_estimate_growth": null, "future_revenue_estimate_growth": -20.58, "future_ebit_estimate_growth": -17.7, "future_ebitda_estimate_growth": -13.34, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": -17.61, "future_pretax_income_estimate_growth": -25.4, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712" ], "revenue_estimate": [ 4, 4.58, 4.54, 5, 5, 5, 5 ], "ebit_estimate": [ -33.9, -36.15, -40.18, -39.5, -41.5, -46.5, -50 ], "ebitda_estimate": [ null, null, null, null, null, null, null ], "net_income_estimate": [ -29.23, -31.4, -35.08, -38.4, -38.4, -43.4, -47.4 ], "per_share_eps_estimate": [ -0.23, -0.25, -0.27, -0.28, -0.26, -0.29, -0.3 ], "eps_nri_estimate": [ -0.23, -0.25, -0.26, -0.26, -0.26, -0.27, -0.28 ], "dividend_estimate": [ null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null ], "pretax_income_estimate": [ -29.03, -31.73, -36.77, -38.4, -38.4, -43.4, -47.4 ], "operating_cash_flow_per_share_estimate": [ -0.13, -0.17, -0.18, null, null, null, null ], "roa_estimate": [ -7.9, -9.1, -10.5, null, null, null, null ], "roe_estimate": [ -11.3, -13.5, -16.5, null, null, null, null ], "gross_margin_estimate": [ 100, 100, 100, 100, 100, 100, 100 ], "operating_cash_flow_estimate": [ -16.39, -21.43, -22.69, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, null, null, null ], "long_term_growth_rate_mean": 0, "long_term_revenue_growth_rate_mean": "-20.58", "future_per_share_eps_estimate_growth": null, "future_eps_nri_estimate_growth": null, "future_revenue_estimate_growth": -20.58, "future_ebit_estimate_growth": -17.7, "future_ebitda_estimate_growth": -13.34, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": -17.61, "future_pretax_income_estimate_growth": -25.4, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }